Eltagonde, Rowena C.
HRN: 10-89-51 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/10/2024
CLINDAMYCIN 300MG (CAP)
11/10/2024
11/17/2024
PO
300 Mg
TID
Avulsed Wound
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes